Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2023 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine...
March 27, 2023 07:50 ET | Source: Vaxxinity, Inc.

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
March 21, 2023 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Joins TransCelerate Research and Development Consortium

CAPE CANAVERAL, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that...
March 20, 2023 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

CAPE CANAVERAL, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that...
March 02, 2023 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

CAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that...
February 01, 2023 19:40 ET | Source: Vaxxinity, Inc.

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories (“VaxxLabs”) in Cape Canaveral, Fla., as...
January 05, 2023 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference

DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
December 02, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized...
November 10, 2022 07:30 ET | Source: Vaxxinity, Inc.

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in...
November 03, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022

Featuring subject matter experts in neuroscience, migraine and hypercholesterolemia DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...